New combo therapy aims to supercharge immune attack on tough cancers

NCT ID NCT04021043

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of three immunotherapy drugs (ipilimumab, nivolumab, and BMS-986156) with or without precise radiation therapy in 51 people with advanced solid cancers that had spread to the liver or lungs. The goal was to find the safest dose of BMS-986156 and see if adding radiation helps the immune system fight tumors better. The trial is complete, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Immunotherapy drugs (ipilimumab, nivolumab, BMS-986156) and stereotactic body radiation therapy
What this could lead to
If it works, this could point toward a more effective treatment combination for advanced cancers that have spread to the liver or lungs.
What could go wrong
This is an early-phase trial with only 51 participants, so results may not apply to everyone. The combination may cause significant side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.